

Zeyzelf®

twice weekly rivastigmine transdermal patch

Zeyzelf® rivastigmine twice weekly transdermal patch

Offer your mild to moderately severe Alzheimer's Dementia patients established efficacy with the convenience of twice weekly application.[1]

Zeyzelf® is indicated for the symptomatic treatment of mild to moderately severe Alzheimer's Dementia.[1]

Prescribing information and adverse event information can be found by scanning or clicking the QR code on the back page.

For further information please visit:
www.zeyzelf.com

UK-ZEY-95a | May 2026

Luye Pharma

Zeyzelf® provides established efficacy with the convenience of twice weekly application

Zeyzelf® (rivastigmine) is the only twice weekly transdermal patch available in the UK for the treatment of mild to moderately severe Alzheimer's Dementia (AD).[1]

Zeyzelf® is a translucent polymer matrix patch designed to allow release of rivastigmine for up to 4 days, including an adhesive cover to optimise adhesion.[1]



Images not to scale, but proportionate.

Zeyzelf® patch



Adhesive cover

Developed by Luye Pharma, Zeyzelf® offers a convenient and effective alternative to oral AChE inhibitors, addressing key challenges in AD management.



The patch is available in 4.6mg and 9.5mg dose strengths.

*The adhesive cover can be written on to remind patients/carers when the patch was applied and/or when it should be removed to aid adherence.

Zeyzelf®

Prescribe by brand

Prescribing Zeyzelf® by brand is less expensive than prescribing rivastigmine generically, costing £35.09 for a 28-day supply compared to £77.97*.[20]

Zeyzelf's manufacturer, Luye Pharma, produces all its transdermal products in its dedicated European production facility, providing greater oversight of the entire supply chain and reliability for clinicians, pharmacists and patients.

Reduce the risk of dispensing errors

To ensure patients receive Zeyzelf® twice weekly rivastigmine patches and to reduce the risks of dispensing errors, it is important that prescriptions are written by brand.[2]



* £77.97 is for a 30 day supply

Nice guidance NG97:[13]



Rivastigmine is a recommended AChE inhibitor for managing mild to moderate Alzheimer's disease.

When prescribing an AChE, treatment should usually be started with the drug with the lowest acquisition cost. However, an alternative AChE inhibitor may be prescribed if it is more suitable, considering factors like side effects, expectations about adherence, medical comorbidity, potential drug interactions and dosing schedules.

Zeyzelf® demonstrates improved outcomes compared to single day rivastigmine patches[12]

Improved Adherence



of caregivers **expressed a direct preference** for the twice weekly patch versus the daily patch for ease of use, ease following the schedule and ease of adherence with treatment.[3, 12]

Improved Patient Compliance




of caregivers reported that the patient always took the twice weekly patch as prescribed, **versus 29.3%** of patients taking the daily patch.[3, 12]

Improved Satisfaction



of clinicians reported high/very high satisfaction with twice weekly patches in nearly **80%** of patients.[3] **More than a third of physician recommended switching** from daily to twice weekly patches.[4]

Improved Patient Condition



of clinicians said the patient's condition taking the twice weekly patch was **very much improved to minimally improved.**[3] Clinicians reported more **satisfactory drug adherence** in patients with the twice weekly patch.[4]



Real-world assessment of caregiver preference and compliance to treatment with twice weekly versus daily rivastigmine patches in Alzheimer's disease.

Extracted from García-Alberca J et al. Journal of Alzheimer's Disease, November 2024
A study of 92 patients who had been treated with daily rivastigmine patch for at least six months prior to switching to twice weekly patch were evaluated at entry, 12 and 24 weeks using the Alzheimer's Disease Caregiver Preference Questionnaire.

To access the full scientific publication scan QR code:

Zeyzelf®

Step one

Delivery with the transdermal patch



Step two

Protect with the adhesive cover



*The adhesive cover can be written on to remind patients/carers when the patch was applied and/or when it should be removed to aid adherence.

twice a week

The only twice weekly transdermal rivastigmine patch

Zeyzelf®

Step

one





Delivery with the transdermal patch

The benefit of transdermal delivery


Step one

Addressing the Challenges in patient care

Dysphagia[14]

Dysphagia (difficulty swallowing) is common among older adults with AD and can make it challenging for patients to adhere to oral AChE inhibitor treatments like donepezil or galantamine tablets or rivastigmine capsules.

Experienced dysphagia



63.9% and 90% of patients with mild and moderate Alzheimer's respectively experienced dysphagia compared with **40% of cognitively intact patients**.[14]

Prevalence of dysphagia



in moderate to severe dementia however, swallowing difficulties arise from the early stages of the Alzheimer's Disease.[18]



Transdermal patches such as Zeyzelf® offer a non-oral option for patients who may have trouble swallowing pills, ensures consistent delivery of medication and may reduce the risk of missed doses due to swallowing issues.[19] Additionally, studies have shown that transdermal administration can improve treatment adherence and patient comfort compared to oral forms.[18]


Drug-drug interactions

When managing complex treatment regimens for AD patients, considering the drug-drug interaction potential of AChE inhibitors can help optimise therapy and reduce the risk of adverse effects.

Zeyzelf® twice weekly patches offer significant advantages for AD patients, particularly in terms of drug-drug interactions. Unlike other AChE inhibitors, rivastigmine demonstrates a low potential for drug-drug interactions, making it an option for patients on polypharmacy medications.[1]

Bypassing the first-pass metabolism in the liver, the patch further reduces the risk of interactions with other drugs. This is especially beneficial for elderly patients who may have compromised liver function or who may be on multiple medications that are metabolised by the liver.[8]

For healthcare providers managing complex treatment regimens, the low interaction potential of rivastigmine patches may help simplify medication management and reduce the need for dose adjustments or frequent monitoring.[18]



14. Farlow MR. Int J Clin Pract Suppl. 2002127):37;(–44. https://pubmed.ncbi.nlm.nih.gov/12139366/. (Last accessed June 2025).
18. Guener M, et al. BMC Geriatrics. 2023;23:304. https://pubmed.ncbi.nlm.nih.gov/37198547/. (Last accessed June 2025).

Zeyzelf®

Side effects[3,15,19]

The rivastigmine transdermal patch tends to have a favourable side effect profile, particularly regarding gastrointestinal effects and overall tolerability.

Zeyzelf's transdermal delivery system generally has a lower propensity to cause side effects most commonly associated with oral AChE inhibitors from 1 in 10 to 1 in 100 (see page 21).

Gastrointestinal (GI) issues[10]

GI side effects are among the most common Adverse Events (AEs) associated with oral AChE inhibitors in AD, sometimes warranting drug alternatives.

Consequently, the transdermal route minimises common side effects associated with oral AChEs, like nausea, vomiting and diarrhoea:

This improved tolerability is particularly beneficial for older patients who may be more susceptible to GI issues.[21]

Transdermal delivery in AD

Rivastigmine is the only acetylcholinesterase (AChE) inhibitor that is available in a transdermal formulation in the UK.

Transdermal patches offer superior tolerability vs orally administered rivastigmine.4*

Fewer patients reported nausea



and vomiting



on transdermal patches compared with oral rivastigmine.*[4]

Transdermal administration delivers reduction in certain side effects vs oral rivastigmine due to:[4,16]

- Avoiding the first pass effects[15] Lowered maximum plasma concentration (Cmax) and prolonged time to reach Cmax (Tmax) for the same exposure[4]
- Reduced fluctuations of plasma drug levels and continuous delivery[4,16]

If adverse events occur, drug delivery can be promptly ceased by simple patch removal.[15] In addition to lower risk of side effects, transdermal route of administration can provide greater adherence to the treatment regimen and has less risk of dose dumping compared with the oral route. This is especially important in older patients who may need concomitant treatment for multiple conditions.[29]

*Data from a study comparing 9.5 mg/24 h daily patch (n=229) vs 12 mg/day oral rivastigmine (n=266).[3]

Step one

94.6% compliance vs 29.3% of patients taking the daily patch after 24 weeks

Compliance and caregiver burden

At 24 weeks, patient compliance was significantly better with the twice weekly patch than with the daily patch (p=0.002).

Caregiver burden significantly improved at the end of the treatment. Sixty five (70.7%) caregivers at week 12 and 87 (94.6%) caregivers at week 24 reported that the patient always took the twice weekly patch as prescribed versus 27 (29.3%) of patients taking the daily patch.




Figure 1. Caregiver preference and satisfaction and compliance with treatment. (A) Caregiver preference and reasons provided for preference for twice weekly.

A study comparing the twice weekly Zeyzelf® patch and Exelon® daily patch showed Zeyzelf® had better adhesion properties despite the longer dosing intervals.[8]

Zeyzelf®

Step two



Protect with the adhesive cover

Security and peace of mind

*The adhesive cover can be written on to remind patients/carers when the patch was applied and/or when it should be removed to aid adherence.

Step two

Protect with the adhesive cover

Importance of adhesion

Skin adhesion is one of the most important functional properties for a transdermal patch and is critical to the tolerability, efficacy and quality of the patch.[6]

Zeyzelf® twice weekly patches come with an oval shaped adhesive cover to optimise adherence to the skin. In a study comparing the twice weekly Zeyzelf® patch and the Exelon daily patch, Zeyzelf® demonstrated superior adhesion properties compared to the Exelon daily patch, despite the longer dosing interval.[5]

Satisfactory adhesion[5]



Zeyzelf® twice weekly patches | **Exelon patches**

The Zeyzelf® twice weekly patch with its adhesive cover provides security with peace of mind for the patients and their caregivers.

5. Figures based on data from Schurad B, et al.

Visual indicator of compliance[1]

Zeyzelf® twice weekly patches offer a unique and simple solution to improve medication adherence in Alzheimer's patients:

Visual marker
Helping minimise the risk of multiple dosing errors

Direct Notation: The Zeyzelf® patch cover allows for direct writing of the date and time of application, providing a clear visual indicator of when the patch was last changed



*The adhesive cover can be written on to remind patients/carers when the patch was applied and/or when it should be removed to aid adherence.

Zeyzelf®

Cost[1,11,31]

Zeyzelf® is the least expensive rivastigmine transdermal patch for the NHS.

Following changes to the Drug Tariff, Zeyzelf® twice weekly patches are now the least expensive rivastigmine patch for Alzheimer's dementia patients.[31]

- Improved patient outcomes, adherence, and reduced care burden[12]
- Cost effective – the least expensive rivastigmine transdermal patch for the NHS[31]
- Resilient supply chain assured by the manufacturer Luye

List price costs of other available single day rivastigmine patches are shown below for comparison.

Competitive price



Less expensive
than other daily rivastigmine patches*



Brand Name	Number of patches	Manufacturer	4.6mg/24h	9.5mg/24h	13.3mg/24h
Zeyzelf®	8 patches*	Luye	£35.09	£35.09	n/a
Exelon	30 patches	Novartis	£77.97	£77.97	£77.97
Almuriva	30 patches	Sandoz	£77.97	£77.97	£77.97
Erastig	30 patches	Teva	n/a	n/a	£73.90
Alzakt	30 patches	Dr Reddys	£77.97	£77.97	n/a
Drug Tariff (INN) (Generic or brand)			£77.97	£77.97	£77.97

*8 patches of Zeyzelf® provides 28 days treatment

This table has been compiled from data on: https://dmd-browser.nhsbsa.nhs.uk/
* Zeyzelf costs £35.09 for a 28 day supply (8 patches) compared to £77.97 for a 30 day supply of daily patches (4.6mg/24hr and 9.5mg/24hr).



Zeyzelf®

twice a week

The only twice weekly transdermal rivastigmine patch

twice a week

The benefits of transdermal delivery



That help address the challenges in patient care

Zeyzelf® is the only transdermal rivastigmine patch with twice weekly application[1]

Less frequent application vs a daily patch gives the option of dosing (application) free days for the carer and patients, e.g., weekends could be dosing (application) free if the patches are applied on a Thursday and Monday or Friday and Tuesday.

Establishing fixed days of application will help the patient and caregiver to maintain a routine and adherence to the medication.[5]

Application of Zeyzelf® patch and adhesive cover[1]

With the ease of fixed day twice weekly dosing, carers can more easily plan the dosing schedule to the patient's and their own convenience.[1]

Example schematic representation comparing patch application of Zeyzelf to a daily patch

	Mon	Tue	Wed	Thur	Fri	Sat	Sun
Zeyzelf® twice weekly Transdermal Patch	■				■		
Exelon® daily Transdermal Patch	●	●	●	●	●	●	●

Example of a dosing schedule. Twice weekly patches should be applied on fixed days, at an interval of 4 and 3 days, respectively.[1]

Instructions for use

For information on Instructions for use including medication record sheets for patients that have been prescribed Zeyzelf Patch (rivastigminetransdermal system) to ensure the correct use of the patch please scan the QR code
Or visit:
https://www.medicines.org.uk/emc/product/14957/rmms

Zeyzelf®

The benefits of twice weekly administration[1]

Helping to simplify the lives of patients as well as their caregivers with:

- Reduced pill burden for patients with multimorbidity
- Suitable for patients who have trouble with, or are unable or unwilling to swallow pills or difficulty in swallowing, in general - a trait closely related to frailty in patients with mild to moderate AD[18]
- Reduced caregiver burden due to application twice a week instead of daily

To learn more about Patch and adhesive cover application watch our 'How to, videos by scanning the QR code:



twice a week

Changing medication

Initiating and changing to Zeyzelf® twice weekly transdermal patch

Rivastigmine daily patches to Zeyzelf® twice weekly patches

4.6mg/24h (DAILY) ····› 4.6mg/24h (TWICE A WEEK)

9.5mg/24 h (DAILY) ····› 9.5mg/24h (TWICE A WEEK)

If the 4.6 mg/24h daily patches are well tolerated for at least 4 weeks, patients can be changed to 9.5mg/24h twice weekly[32]

Donepezil to Zeyzelf®

Recommended dosing:



INITIATION DOSE 4.6mg/24h

for at least 4 weeks at the start of treatment

MAINTENANCE DOSE 9.5mg/24h

0 ····› 1 ····› 2 ····› 3 ····› 4

Patients can be simply changed to Zeyzelf® twice weekly from donepezil treatment.

No washout period is required while changing your patients from donepezil to Zeyzelf® patches. **Immediate change from donepezil to Zeyzelf® can be made** to avoid the potential wash out induced cognitive decline in patients.[28]

Changing patients from donepezil to Zeyzelf® without a wash-out period is well tolerated and does not cause serious adverse events[28]

Oral rivastigmine to Zeyzelf®

Patients treated with rivastigmine capsules or oral solution can be changed to Zeyzelf® twice weekly as follows:[1]

Patients on

3mg/24h ORAL DOSE

6mg/24h ORAL DOSE

Or did not tolerate

9mg/24h ORAL DOSE

CAN BE CHANGED TO AN INTITIAL DOSE OF 4.6mg/24h Zeyzelf® patch ····› 9.5mg/24h THE RECOMMENDED EFFECTIVE DOSE*

If the 4.6 mg/24 h patches are well tolerated for at least 4 weeks, patients should be then changed to 9.5mg/24 h

Patients on a stable and well tolerated oral dose

9mg/24h OR 12mg/24h ····› can be changed to 9.5mg/24h Zeyzelf® patch

It is recommended to apply the first transdermal patch on the day following the last oral dose

*Patients with body weight < 50 kg and those with hepatic impairments may need careful dose titration and close monitoring for side effects.

Summary

Prescribe by brand and reduce the risk of dispensing errors

To ensure patients receive Zeyzelf® twice weekly rivastigmine patches and to reduce the risks of dispensing errors, it is important that prescriptions are written by brand.[2]

Least expensive

Zeyzelf® 4.6mg/24hr and 9.5mg/24 hr patches are **more than 50% less expensive** than any other available rivastigmine patches including when written generically.



Good adhesion:[5]

The Zeyzelf® patch cover **improves adhesion** when compared to the daily Exelon patch, ensuring relaible drug delivery.

Improved adherence and care giver preference

83% of caregivers expressed a direct preference for the twice weekly patch to the daily patch. For ease of use, ease following the schedule and ease of adherence with treatment.

Adhesive cover

Zeyzelf® twice weekly patches come with an oval shaped adhesive cover to optimise adherence to the skin. In a study comparing the twice weekly Zeyzelf® patch and the Exelon daily patch, Zeyzelf® **demonstrated superior adhesion properties** compared to the Exelon daily patch, despite the longer dosing interval.[8]

Visual indicator of compliance:

A unique and simple solution to improve medication adherence in Alzheimer's patients helping minimise the risk of multiple dosing errors. The adhesive cover can be written on with the date of application and/or the date it should be removed helping carers record and track the medication.

Reduced side effects:

By bypassing the gastrointestinal tract, **Zeyzelf® minimises common side effects like nausea, vomiting, and diarrhoea.**

Improved patient outcomes:

Zeyzelf® demonstrates **improved outcomes** compared to single day rivastigmine patches.[12]

Dysphagia

Suitable for patients who have trouble with, or are unable or unwilling to swallow pills or difficulty in swallowing, in general - a trait closely related to frailty in patients with mild to moderate AD.

Reduced gastrointestinal side effects:[3]

As Zeyzelf® is a patch, not a pill, it means it avoids the stomach and the digestive system. This makes it more tolerable and is particularly beneficial for older patients who may have a sensitive stomach or suffer from Gastrointestinal issues (GI).

Care giver satisfaction:[12]

Caregivers indicated **greater satisfaction** with the twice weekly patch versus the daily one. **85.9% of caregivers were satisfied or very satisfied** with the twice weekly patch versus **52.1%** of patients taking the daily patch.

Less caregiver burden:[8]

Thus, the simplification of treatment regimens may assist in reducing the burden on caregivers, which may subsequently result in enhanced medication adherence and **a positive impact on the patient's condition.**



Comparing adverse events[20]

Adverse events	Donepezil (oral)	Rivastigmine (oral)	Rivastigmine (patch)	Galantamine (oral)	Memantine (oral)
Very common (≥ 1/10)	Diarrhoea, nausea, headache	Anorexia, dizziness, nausea, vomiting, diarrhoea		Nausea vomiting	
Common (≥1/100)	Common cold, anorexia, hallucinations, agitation, aggressive behaviour, abnormal dreams and nightmares, syncope, dizziness, insomnia, vomiting, abdominal disturbance, rash, pruritis, muscle cramps, urinary incontinence, fatigue, pain	Decreased appetite, nightmares, agitation, confusion, anxiety, headache, somnolence, tremor abdominal pain and dyspepsia, sweating fatigue and asthenia, malaise, weight loss	Application site skin reactions, urinary incontinence, rash, nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, headache, syncope, dizziness, anxiety, depression, delirium, agitation, anorexia, decreased appetite, urinary tract infection	Decreased appetite, hallucination, depression, syncope, dizziness; tremor, headache, somnolence, lethargy, bradycardia, hypertension, abdominal pain and discomfort, diarrhoea, dyspepsia, muscle spasms, fatigue, asthenia, malaise, weight loss, fall	Drug hypersensitivity, somnolence, dizziness, balance disorders, hypertension, dyspnoea, constipation, elevated liver function test, headache

Table adapted from Taylor DM, et al, The Maudsley Prescribing Guidelines in Psychiatry 2021,14th edition

Zeyzelf®

For further information about Zeyzelf® visit

www.zeyzelf.com

Alternatively scan or click the QR code below:



Zeyzelf®

References

1. Zeyzelf® rivastigmine transdermal patch, Summary of Product Characteristics, Luye Pharma Ltd. https://www.medicines.org.uk/emc/product/14957/smpc#gref. (Last accessed May 2026).
2. BNF listing: https://bnf.nice.org.uk/drugs/rivastigmine/
3 Piñol Ripoll G, Salas Carrillo M. Patient Prefer and Adherence. https://doi.org/10.2147/PPA.S510634. (Last accessed May 2026).
4. Winblad B, et al. Int J Geriatr Psychiatry. 2007;69(4 Suppl 1):S14–22. https://pubmed.ncbi.nlm.nih.gov/17646619/. (Last accessed May 2026).
5. Schurad B, et al. Current Alzheimer Research. 2022;19,541–553. https://pubmed.ncbi.nlm.nih.gov/36017827/. (Last accessed May 2026).
6. Wokovich A M et al. Eur J Pharm Biopharm. 2006;64(1):1–8. https://www.sciencedirect.com/science/article/abs/pii/S0939641106000804. (Last accessed May 2026).
7. Poirier J. Int J Clin Pract Suppl. 2002;(127):6–19. https://pubmed.ncbi.nlm.nih.gov/12139368/. (Last accessed May 2026).
8. Birks JS, et al. Cochrane Database Syst Rev. 2015 Sep 22;9(9):CD001191. https://pmc.ncbi.nlm.nih.gov/articles/PMC7050299/. (Last accessed May 2026).
9. Care and Nursing. Available at: https://careandnursing-magazine.co.uk/treatment-of-alzheimers-disease/. (Last accessed May 2026).
10. Electronic Medicines Compendium (EMC). Zeyzelf® SmPC. Available online at: https://www.medicines.org.uk/emc/product/14957/smpc. (Last accessed May 2026).
11. Comparative costs against non-tablet formulations table. Data on file.
12. García-Alberca JM, De La Guía P, Gris E, et al. Journal of Alzheimer's Disease. 2024;102(3). https://journals.sagepub.com/doi/abs/10.1177/13872877241292018 (Last accessed May 2026).
13. NICE guideline [NG97] June 2018. Available at: https://www.nice.org.uk/guidance/ng97. (Last accessed May 2026).
14. Farlow MR. Int J Clin Pract Suppl. 2002127):37;(–44. https://pubmed.ncbi.nlm.nih.gov/12139366/. (Last accessed May 2026).
15. Grossberg GT, et al. Int J Geriatr Psychiatry. 2000;15(3):242–247. https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1099-1166(200003)15:3%3C242::AID-GPS110%3E3.0.CO;2-7. (Last accessed May 2026).
16. Sozio P, et al. Neuropsychiatr Dis Treat. 2012;8:361–368. https://pmc.ncbi.nlm.nih.gov/articles/PMC3428243/. (Last accessed May 2026).
17. Poison: https://www.poison.org/articles/donepezil-can-be-toxic-if-too-much-is-taken-or-child-swallows-174. (Last accessed May 2026).
18. Guener M, et al. BMC Geriatrics. 2023;23:304. https://pubmed.ncbi.nlm.nih.gov/37198547/. (Last accessed May 2026).
19. Parsons C. Withdrawal of Antidementia Drugs in Older People: Who, When and How? Drugs Aging 2016; 33:545-556. https://pubmed.ncbi.nlm.nih.gov/27393698/. (Last accessed May 2026).
20. David M Taylor et al, The Maudsley Prescribing Guidelines in Psychiatry 2021,14th edition https://onlinelibrary.wiley.com/doi/book/10.1002/9781119870203?msockid=3cd043fed58468bf2ef0563dd43f692b. (Last accessed May 2026).
21. Dumic I, et al. Can J Gastroenterol Hepatol. 2019 Jan 17;2019:6757524.-scale-impact-numbers. https://www.cambridge.org/core/books/abs/reichels-care-of-the-elderly/gastrointestinal-disorders/7D4ACC36F168039C49B403FCD8FC6B75. (Last accessed May 2026).
22. Alzheimer's Society. What are the costs of dementia care in the UK. Available online at: https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-impact-numbers. (Last accessed May 2026).
23. Chen Y, et al. Lancet Public Health. 2023;8(11):e859–e867. https://pubmed.ncbi.nlm.nih.gov/37898518/. (Last accessed May 2026).
24. NHS Oxford Health Library Services. Dementia care. Available online at: https://www.oxfordhealth.nhs.uk/library/cpd-zone/cpd-by-topic/dementia-care/. (Last accessed May 2026).
25. Lakey L, (2009) Counting the cost: Caring for people with dementia on hospital wards published by the Alzheimer's Society. Available online at: https://www.alzheimers.org.uk/sites/default/files/2018-05/Counting_the_cost_report.pdf. (Last accessed May 2026).
26. Patient Information Leaflet. https://www.medicines.org.uk/emc/product/14957/pil. (Last accessed May 2026).
27. Mitchell RJ, et al. Int Psychogeriatr. 2015 Nov;27(11):1757-68. https://www.intpsychogeriatrics.org/article/S1041-6102(24)00675-6/fulltext. (Last accessed May 2026).
28. Sadowsky CH, et al. Prim Care Companion J Clin Psychiatry. 2005;7(2):43–48. https://www.researchgate.net/publication/244949798_Switching_From_Donepezil_to_Rivastigmine_Is_Well_Tolerated. (Last accessed May 2026).
29. Vadivelu N, Hines R L. Clin Interv Aging. 2008;3(3):421–430. https://pmc.ncbi.nlm.nih.gov/articles/PMC2682375/. (Last accessed May 2026).
30. Blesa R, et al. Neurology. 2007;69(4 suppl 1):S23–S28. https://pubmed.ncbi.nlm.nih.gov/17646620/. (Last accessed May 2026).
31. Dm+d. https://dmd-browser.nhsbsa.nhs.uk/. (Last accessed May 2026).
32. Dr Delia Bishara Consultant Pharmacist, Presentation to Boots Pharmacies (Last accessed May 2026).

For further information please visit:

www.zeyzelf.com

Prescribing Information and Adverse Event Reporting can be found by scanning or clicking the QR code:

UK-ZEY-95a | May 2026

Luye Pharma